As of November 10, 2026, Foghorn Therapeutics Inc. is a publicly traded company (Nasdaq: FHTX). The largest holder reporting an active stake on Schedule 13D is Flagship Ventures Fund V, L.P., at 27.2%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BVF Partners (14.3%), Fidelity (FMR) (11.6%), Deerfield Mgmt, L.P. (8.64%) (Schedule 13D/A, January 13, 2026).
Is this your company?
About to sign with, pay or invest in Foghorn Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Foghorn Therapeutics Inc. a real, registered company?
- Foghorn Therapeutics Inc. files with the SEC under CIK 1822462 (its SEC filings).
- Its shares are listed under the ticker FHTX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Foghorn Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-10-01, about 65 jobs).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BVF Partners (filed 2026-10-05).
Who are Foghorn Therapeutics Inc.'s owners and officers?
Foghorn Therapeutics Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-05 | Bvf Partners L P/Il | 14.3% |
| Schedule 13G/A, 2026-05-15 | Bvf Partners L P/Il | 9.99% |
| Schedule 13G/A, 2026-05-14 | Deerfield Mgmt, L.P. | 8.64% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 11.6% |
| Schedule 13D/A, 2026-01-13 | Flagship Ventures Fund V, L.P. | 27.2% |
Questions about who owns Foghorn Therapeutics Inc.
Who owns Foghorn Therapeutics Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Foghorn Therapeutics Inc.: Flagship Ventures Fund V, L.P. (27.2%, Schedule 13D/A, filed 2026-01-13), Bvf Partners L P/Il (14.3%, Schedule 13G/A, filed 2026-10-05), Fmr LLC (11.6%, Schedule 13G/A, filed 2026-05-06) and Deerfield Mgmt, L.P. (8.64%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Foghorn Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Foghorn Therapeutics Inc. on this page are Flagship Ventures Fund V, L.P. (27.2%), Bvf Partners L P/Il (14.3%) and Fmr LLC (11.6%).
When did Flagship Ventures Fund V, L.P. buy into Foghorn Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Flagship Ventures Fund V, L.P. on this page is the Schedule 13D/A, filed 2026-01-13, reporting 27.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Foghorn Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Foghorn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Foghorn Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Foghorn Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- BVF Partners, a 10% owner: 619,258 shares (1.0% of shares outstanding), on a joint filing (Form 3, 2026-10-05).
- Biotechnology Value Fund LP, a 10% owner: 619,258 shares (1.0% of shares outstanding), on a joint filing (Form 3, 2026-10-05).
- BVF I GP LLC, a 10% owner: 619,258 shares (1.0% of shares outstanding), on a joint filing (Form 3, 2026-10-05).
- Biotechnology Value Fund II LP, a 10% owner: 619,258 shares (1.0% of shares outstanding), on a joint filing (Form 3, 2026-10-05).
- BVF II GP LLC, a 10% owner: 619,258 shares (1.0% of shares outstanding), on a joint filing (Form 3, 2026-10-05).
Shares outstanding: 59,962,650 as of 2026-10-30, from the company's latest SEC cover page.
How much has Foghorn Therapeutics Inc. raised?
No fundraising or offering filing from Foghorn Therapeutics Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-10-01).
Keep reading
More on Foghorn Therapeutics Inc. and the records around it.
Foghorn Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/foghorn-therapeutics